AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

Trump’s threat to slap a 200% tariff on pharmaceutical imports, made offhandedly at a cabinet meeting, has sparked a selloff in some drug stocks, but analysts say the number may be more political ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Johnson and Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

US President Donald Trump's 200% tariff threat on the pharmaceutical industry is a "shock" that will reverberate through ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

Targeting European allies won't fix any of our problems with China, or improve health care, writes Josh Steuterman.